Workflow
汤臣倍健(300146) - 2024 Q1 - 季度财报
300146By-health(300146)2024-04-25 13:11

Financial Performance - The company's revenue for Q1 2024 was ¥2,646,096,290.74, a decrease of 14.87% compared to ¥3,108,119,772.05 in the same period last year[3] - The net profit attributable to shareholders for Q1 2024 was ¥726,556,175.48, down 29.43% from ¥1,029,519,641.37 year-on-year[3] - The basic earnings per share for Q1 2024 was ¥0.43, a decline of 29.51% compared to ¥0.61 in the previous year[3] - The net profit for the current period is approximately ¥718.95 million, a decrease of 31.5% compared to ¥1.05 billion in the previous period[20] - The total comprehensive income attributable to the parent company's owners is approximately ¥635.07 million, down from ¥978.80 million, reflecting a decline of 35.1%[21] - The total profit before tax for the current period is approximately ¥896.23 million, down from ¥1.33 billion, a decrease of 32.7%[20] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥14,675,412,881.22, representing a decrease of 2.80% from ¥15,098,017,428.13 at the end of the previous year[3] - The company’s total assets included cash and cash equivalents of RMB 3.092 billion, down from RMB 3.327 billion at the beginning of the period[15] - Total current assets increased slightly to ¥8,399,348,983.02 from ¥8,312,926,267.55, an increase of approximately 1.0%[18] - Total current liabilities decreased to ¥1,612,772,946.93 from ¥2,463,073,926.72, a reduction of about 34.6%[17] Cash Flow - The net cash flow from operating activities for Q1 2024 was ¥709,494,086.61, a decrease of 28.67% compared to ¥994,652,011.53 in the previous year[3] - Cash flow from operating activities generated a net amount of approximately ¥149.41 million, significantly lower than ¥665.86 million in the previous period, indicating a decrease of 77.6%[22] - The company reported cash inflows from investment activities totaling approximately ¥1.73 billion, compared to ¥2.85 billion in the previous period, a decrease of 39.3%[23] - The cash flow from financing activities resulted in a net outflow of approximately ¥202.42 million, compared to a smaller outflow of ¥6.98 million in the previous period[23] - Total cash and cash equivalents decreased by 231.29 million, a decline of 134.99%, primarily due to reduced collections and increased stock repurchase payments[7] Revenue Breakdown - The main brand "汤臣倍健" generated revenue of RMB 1.545 billion, a decline of 17.74% year-over-year[13] - The online sales channel achieved revenue of RMB 909 million, reflecting a decrease of 26.53% year-over-year[14] - The joint care brand "健力多" reported revenue of RMB 373 million, down 2.06% year-over-year[13] - The overseas brand "lifespace" generated revenue of RMB 253 million, a decrease of 5.08% year-over-year[13] Other Financial Metrics - The weighted average return on equity for Q1 2024 was 5.88%, down 3.33 percentage points from 9.21% in the same period last year[3] - Interest expenses for the current period were 18.64 million, an increase of 1,124.98% compared to the same period last year, mainly due to increased interest expenses on lease liabilities[6] - Other income for the current period was 121.19 million, an increase of 182.31% compared to the same period last year, mainly due to increased VAT deductions[6] - Investment income for the current period was 236.22 million, a decrease of 35.98% compared to the same period last year, mainly due to reduced income from financial products[6] Shareholder Activities - As of March 31, 2024, the company repurchased a total of 13,736,987 shares, accounting for 0.81% of the total share capital[14] - The maximum and minimum repurchase prices were RMB 18.07 and RMB 14.19 per share, respectively, with a total expenditure of RMB 216,755,528.08[14] - The balance of treasury stock at the end of the period was 216.91 million, an increase of 1,105.25% compared to the beginning of the year, mainly due to share repurchases during the reporting period[6] Operational Changes - The company plans to continue its "scientific nutrition" strategy and product innovation in 2024[13] - The company experienced a significant increase in employee compensation payments, totaling approximately ¥366.29 million, compared to ¥286.80 million in the previous period, an increase of 27.7%[22]